Carisma Therapeutics Inc.
DelistedCIK 1485003fmd_0TAVK5DAWFFCJXEWM6N0RF21KQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2025, 52 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 30 | 0 | 0 | 0 | 11 | 27 | 10 | 15 | 20 |
| Research and development | 26 | 13 | 13 | 14 | 25 | 29 | 25 | 57 | 74 | 60 |
| Total operating expenses | 36 | 27 | 30 | 35 | 108 | 32 | 35 | 66 | 104 | 82 |
| Operating income | (35) | 3 | (29) | (35) | (108) | (21) | (9) | (56) | (89) | (62) |
| Interest expense | 0 | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | 0 | 0 | 2 | – | – |
| Other non-operating income (expense) | 2 | (1) | 0 | 1 | 1 | (0) | (0) | 0 | – | – |
| Income before taxes | (33) | 2 | (29) | (34) | (108) | (21) | (9) | (24) | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 1 | (8) | (4) | – | – |
| Net income from continuing operations | (33) | 2 | (29) | (34) | (108) | (22) | (0) | (20) | – | – |
| Net income | (33) | 2 | (29) | (34) | (108) | (22) | (0) | (61) | (87) | (60) |
| Net income to common shareholders | (33) | 2 | – | – | (108) | (23) | (0) | (20) | – | – |